2010 ART Cohort | 2011 ART Cohort | 2012 ART Cohort | 2013 ART Cohort | 2014 ART Cohort | 2015 ART Cohort | 2016 ART Cohort | Total | |
---|---|---|---|---|---|---|---|---|
Total # of patients | 3914 | 5863 | 8641 | 10,812 | 11,629 | 10,325 | 1890 | 53,074 |
% with no test | 56.6% | 55.6% | 57.5% | 58.0% | 54.0% | 52.7% | 48.3% | 55.3% |
% suppressed | 29.4% | 30.1% | 28.4% | 28.2% | 32.4% | 32.8% | 36.3% | 30.6% |
% unsuppresseda | 14.0% | 14.3% | 14.1% | 13.8% | 13.6% | 14.5% | 15.4% | 14.1% |
Among patients with initial unsuppressed result | ||||||||
# unsuppressed | 549 | 841 | 1213 | 1494 | 1588 | 1492 | 291 | 7468 |
% re-suppressed | 16.4% | 12.0% | 13.9% | 12.6% | 11.6% | 10.9% | 10.3% | 12.4% |
% unsuppressed followed by no test | 50.6% | 55.8% | 57.3% | 57.5% | 61.2% | 64.6% | 70.1% | 59.5% |
% confirmed failure | 33.0% | 32.2% | 28.8% | 29.9% | 27.2% | 24.5% | 19.6% | 28.1% |
Among patients with confirmed failure | ||||||||
# confirmed failure | 181 | 271 | 349 | 447 | 431 | 366 | 57 | 2102 |
% with strong adherence | 47.0% | 46.1% | 47.9% | 43.8% | 43.9% | 40.7% | 49.1% | 44.7% |
% with weak adherence | 53.0% | 53.9% | 52.1% | 56.2% | 56.1% | 59.3% | 50.9% | 55.3% |